focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 375.00
Bid: 370.00
Ask: 380.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.703%)
Open: 375.00
High: 375.00
Low: 375.00
Prev. Close: 375.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit

Tue, 05th Mar 2024 20:43

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Beeks Financial Cloud Group PLC - Glasgow-based cloud computing and connectivity provider - Swings to pretax profit of GBP158,000 in the six months to December 31, from a loss of GBP762,000 a year prior. Revenue climbs 25% to GBP13.0 million from GBP10.4 million. Cost of sales increase 31% to GBP8.2 million from GBP6.2 million, while admin expenses decrease 4.2% to GBP4.7 million from GBP4.9 million. Looking ahead, Chief Executive Officer Gordon McArthur says the company is confident as it was underlining "the size of the opportunity we are addressing. Financial markets are still only at the start of the journey to the cloud. With our proven offering and growing tier 1 customer base, which includes some of the largest financial organisations in the world, as well as our increasing profit margins and cash generation, we have never been better placed to seize the opportunity. Our focus for the second half remains the conversion of our significant pipeline."

----------

dotdigital Group PLC - London-based online marketing company - Pretax profit edges down negligibly to GBP7.38 million in the six months to December 31, from GBP7.42 million a year prior. Revenue however grows 15% to GBP38.7 million from GBP33.8 million. Cost of sales increase 14% to GBP8.0 million from GBP7.1 million. Administrative expenses increase 16% to GBP22.4 million from GBP19.2 million. Looking ahead, the company says it enters the second financial half "with good trading momentum and the ability to attract higher value deals, underpinned by continuous product enhancements to drive cross- and up-sells from the existing base." It adds: "We remain confident in the group's ability to continue to execute against its stated strategy and meet market expectations."

----------

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Confirms 2023 results it had announced in January. Further, expects core revenue growth of between none and 5% in 2024 compared to 2023. Expects strategic platform license programme-related revenue of around USD3 million for the year, down sharply from USD11.4 million in 2023. CEO Maher Masoud says: "As we continue to expand our SPL portfolio this year, we remain confident in our ability to support our current and prospective clients as new waves of next-generation cell therapies come to market."

----------

Origin Enterprises PLC - Dublin-based agronomy services firm - Pretax profit dives 96% to EUR5.3 million in the six months to January 31, from EUR13.3 million a year prior. Revenue drops 28% to EUR854.9 million from EUR1.18 billion. Notes an expected correction in global feed and fertiliser raw materials regarding decline in revenue. Despite the results, maintains interim dividend at 3.15 euro cents per share. Looking ahead, says on-farm sentiment remains cautious as growers shift towards spring planting and seek to optimise yields from a reduced autumn/winter planted area. Further, expects financial 2024 earnings per share between 44 and 49 euro cents, reflecting adverse weather. This compares to EPS of 45.24c Origin Enterprises had reported for financial 2023.

----------

Thor Energy PLC - US and Australia-focused mineral exploration company - Pretax loss widens to GBP2.3 million in the six months to December 31, from GBP8,000 a year prior. Posts no revenue. Notes costs regarding a write off of exploration assets of around GBP1.9 million in the most recent half-year, compared to no such cost a year prior. Managing Director Nicole Warland says: "After ending the year with consistent high-grade uranium results from our 2023 drilling program, we are optimistic about our 2024 drilling programs as we continue to strategically position our portfolio towards advancing our 'green energy' projects in the US." She adds: "With a strong pipeline of news flow expected for the coming months and project milestones across the portfolio, we anticipate 2024 to provide significant progress in our key assets and we will provide further updates in due course."

----------

Time Out Group PLC - Global media and hospitality business - Pretax loss narrows 63% to GBP4.6 million in the six months to December 31, from GBP12.5 million a year prior. Revenue falls 2.4% to GBP52.5 million from GBP53.8 million. However, like-for-like revenue in constant currency climbs 6.9% to GBP54.9 million from GBP51.4 million. Time Out says it has made "significant" further progress in driving profitability and operational cash generation. It says it has several potential growth avenues, citing collaboration with leading landlords and developers.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 Jul 2023 14:49

MaxCyte inks platform licensing deal with Lyell

(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.

Read more
6 Jul 2023 13:58

MaxCyte inks strategic platform license with Lyell Immunopharma

(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company.

Read more
11 May 2023 12:10

MaxCyte revises guidance after weaker first quarter

(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.

Read more
11 May 2023 10:26

MaxCyte revenue declines, operating loss widens as costs increase

(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher.

Read more
4 May 2023 17:26

IN BRIEF: MaxCyte signs strategic platform license with Walking Fish

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.

Read more
3 May 2023 14:50

UK earnings, trading statements calendar - next 7 days

Thursday 4 May 
Apax Global Alpha LtdQ1 Results
BAE Systems PLCTrading Statement
Cardiff Property PLCHalf Year Results
Derwent London PLCTrading Statement
e-Therapeutics PLCFull Year Results
Glanbia PLCQ1 Results
IMI PLCTrading Statement
Mondi PLCTrading Statement
Morgan Sindall Group PLCTrading Statement
Next PLCTrading Statement
Rathbones Group PLCTrading Statement
Shell PLCQ1 Results
Spirent Communications PLCTrading Statement
Trainline PLCFull Year Results
Virgin Wines UK PLCHalf Year Results
Wheaton Precious MetalsQ1 Results
Friday 5 May 
Eqtec PLCFull Year Results
InterContinental Hotels Group PLCTrading Statement
International Consolidated Airlines Group SAQ1 Results
Monday 8 May 
no events scheduled 
Tuesday 9 May 
Kosmos Energy LtdQ1 Results
Tialis Essential IT PLCFull Year Results
Treatt PLCHalf Year Results
Wednesday 10 May 
Anexo Group PLCFull Year Results
Asos PLCHalf Year Results
Compass Group PLCHalf Year Results
Directa Plus PLCFull Year Results
Georgia Capital PLCQ1 Results
MaxCyte IncQ1 Results
Spirax-Sarco Engineering PLCTrading Statement
Valeura Energy IncQ1 Results
Vertu Motors PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
30 Mar 2023 16:03

IN BRIEF: MaxCyte Chair Richard Douglas buys USD350,000 in shares

MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.

Read more
28 Mar 2023 13:03

MaxCyte installs Douglas Swirsky as its new finance chief

(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.

Read more
28 Mar 2023 10:44

MaxCyte appoints new chief financial officer, effective immediately

(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.

Read more
16 Mar 2023 15:01

MaxCyte expecting strong 2023 after decent results

(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.

Read more
16 Mar 2023 12:20

MaxCyte revenue up as growth expected in 2023; net loss widens

(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023.

Read more
8 Mar 2023 18:14

IN BRIEF: MaxCyte names members of new scientific advisory board

MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka.

Read more
8 Mar 2023 15:54

UK earnings, trading statements calendar - next 7 days

Thursday 9 March 
Aviva PLCFull Year Results
ConvaTec Group PLCFull Year Results
Digital 9 Infrastructure PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
DS Smith PLCTrading Statement
Endeavour Mining PLCFull Year Results
Entain PLCFull Year Results
Forterra PLCFull Year Results
Franchise Brands PLCFull Year Results
Hammerson PLCFull Year Results
Harbour Energy PLCFull Year Results
Hansard Global PLCHalf Year Results
Headlam Group PLCFull Year Results
Informa PLCFull Year Results
Kier Group PLCHalf Year Results
M&G PLCFull Year Results
Network International Holdings PLCFull Year Results
Oakley Capital Investments LtdFull Year Results
PageGroup PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Spirax-Sarco Engineering PLCFull Year Results
Volution Group PLCHalf Year Results
Wheaton Precious Metals CorpFull Year Results
Friday 10 March 
Allianz Technology Trust PLCFull Year Results
Berkeley Group HoldingsTrading Statement
BP PLCFull Year Results
FBD Holdings PLCFull Year Results
Lancashire Holdings LtdFull Year Results
Mineral & Financial Investments LtdHalf Year Results
Robert Walters PLCFull Year Results
Monday 13 March 
Direct Line Insurance Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
HgCapital Trust PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Nightcap PLCHalf Year Results
Phoenix Group Holdings PLCFull Year Results
Stelrad Group PLCFull Year Results
Tuesday 14 March 
Aptamer Group PLCHalf Year Results
Close Brothers Group PLCHalf Year Results
Costain Group PLCFull Year Results
Eagle Eye Solutions Group PLCHalf Year Results
Genuit Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
H&T Group PLCFull Year Results
Harworth Group PLCFull Year Results
Litigation Capital Management LtdHalf Year Results
Midwich Group PLCFull Year Results
Old Mutual LtdFull Year Results
PCI-PAL PLCHalf Year Results
Pennon Group PLCTrading Statement
Sabre Insurance Group PLCFull Year Results
Smart Metering Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Virgin Wines UK PLCHalf Year Results
Yu Group PLCFull Year Results
Wednesday 15 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
FDM Group Holdings PLCFull Year Results
Ferrexpo PLCFull Year Results
Foresight Solar Fund LtdFull Year Results
IG Group Holdings PLCQ3 Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Marshalls PLCFull Year Results
MaxCyte IncFull Year Results
Prudential PLCFull Year Results
Trainline PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
7 Mar 2023 10:51

MaxCyte revenue grows in 2022, expects further revenue climb in 2023

(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023.

Read more
7 Mar 2023 09:32

MaxCyte flags 2022 revenue growth, sets new guidance

(Sharecast News) - Cell engineering technology company MaxCyte said in an update on Tuesday that it was expecting full-year 2022 total revenue of $44.3m, which would represent growth of 31% over 2021.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.